Patient Resources / Clinical Trials
ImmusanT is advancing the development of their lead product, Nexvax2®, which is a therapeutic vaccine designed to protect against the effects of gluten exposure while patients maintain a gluten-free diet. For the Nexvax2® therapy, ImmusanT has successfully established cGMP drug manufacturing, pharmacokinetics and toxicology studies, and preclinical proof-of-concept in a transgenic mouse model. In addition, ImmusanT has completed four Phase 1 clinical trials demonstrating that Nexvax2® is well tolerated, safe, and has relevant bioactivity in human subjects.
Results of the Phase 1 clinical trials of Nexvax2 in celiac disease have informed the dosing plan to be used in a larger, multinational Phase 2 study that is expected to commence in 2018. More details on this Phase 2 study will be posted on clinicaltrials.gov.
Type 1 Diabetes
ImmusanT has also completed discovery work investigating the relationship between Celiac Disease and Type 1 Diabetes at the Joslin Diabetes Center.
If you are interested in learning more about ImmusanT-sponsored clinical trials, please visit our Learn More page.